BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34426077)

  • 1. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
    Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-emptive resection for intraductal papillary mucinous neoplasia - Long-term outcome is similar between non-invasive and early invasive lesions in a tertiary single center.
    Djoumi Y; Sadr-Azodi O; Vujasinovic M; Del Chiaro M; Sparrelid E; Ghorbani P; Holmberg M
    Pancreatology; 2023 Jun; 23(4):389-395. PubMed ID: 37002181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
    Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
    Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation.
    Choi M; Chong JU; Hwang HK; Seo HI; Yang K; Ryu JH; Roh Y; Kim DH; Lee JH; Lee WJ; Choi SH; Kang CM
    J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):671-679. PubMed ID: 34028187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
    Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
    Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma.
    Koh YX; Chok AY; Zheng HL; Tan CS; Goh BK
    Ann Surg Oncol; 2014 Aug; 21(8):2782-800. PubMed ID: 24687151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
    Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
    Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
    [No Abstract]   [Full Text] [Related]  

  • 15. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
    Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
    BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
    Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
    Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
    Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
    Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.